Collectively, these findings uncover a novel molecular mechanism of activation of PTEN/AKT/mTOR signalling pathway by TRIM29 over-expression and may prove clinical useful in NPC therapy. This evidence concerns the gene TRIM29 and nasopharyngeal carcinoma.